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Pebble in a Pond
hy interventional cardiovascular medicine? The question could also be, “why cardiology?” As
he fund of knowledge and skills required expands, it is not possible to master them as a gen-
ralist. Subspecialization develops in every field in response to these pressures. But interven-
ional cardiovascular medicine’s journey to the present and its pathway to the future has been
nique and its impact on medicine profound.
“Like a pebble in a pond”—the analogy fits Andreas Gruentzig’s (Fig. 1) audacious act of
ommitment and conviction in inflating a balloon in the coronary artery of a brave 38-year-
ld, Dolf Bachmann. The “ripples” from this event have spread throughout medicine in ever-
xpanding ways to influence our lives now and well into an unknown future. Let us look at 4
f these ways.
mpact on Patient Care
t is estimated that percutaneous coronary interventions are now performed on 2 million pa-
ients worldwide each year. To what effect? There is not a more effective therapy for disabling
ngina pectoris. Restoration of the supply side of ischemic heart disease has enabled full and
igorous lives for patients previously cautioned to restrict necessary, enjoyable, and beneficial
hysical activity. Acute coronary syndromes have been stabilized without the fear of impending
yocardial infarction. Acute myocardial infarction is interrupted and sometimes aborted by
rompt primary angioplasty, saving countless lives everyday. Patients who could not walk due
o claudication are walking. Those with rheumatic heart disease and congenital heart disease
re having their hearts repaired without necessity of surgical intervention.
mpact on Education
entoring of clinical decisions and procedural skills has long been a tradition in surgery, but
his was brought to new heights when Gruentzig’s openness and communication skills were
oupled with the medium of television. The demonstration courses begun in a small audito-
ium in Zurich and expanded at Emory University in Atlanta provided the initial training for
he first wave of interventionalists. These teaching methods grew and became available to vir-
ually all interventionalists through the “new device” demonstration courses in Santa Barbara
nd Monaco in the late 1980s and early 1990s, and through the interventional mega courses of
ranscatheter Cardiovascular Therapeutics, EuroPCR, Complex Cardiovascular Therapeutics,
he i2 Summit/Society for Cardiac Angiography and Interventions symposium, and many others.
cademic training of interventional cardiologists was formally established in the late 1990s,
ith approval of the curriculum by the Accrediting Council on Graduate Medical Education
nd the certifying examination of the American Board of Internal Medicine. The American
ollege of Cardiology, the Society for Cardiac Angiography and Interventions, the Society for
ascular Surgery, and others have developed training materials and courses to prepare for these
xaminations. To date, almost 6,000 cardiologists have become board certified as competent in
nterventional cardiology. Other specialties have progressed in establishing similar tracks.
mpact on Research
he relative value of an interventional approach to ischemic heart disease has been studied in
ore clinical trials than almost any other field in medicine. Basic research has been stimulated
y the new diseases produced by angioplasty. Acute endothelial and vessel wall damage pro-
uced a clinical correlate of the experimental Foltz model of arterial thrombosis that necessi-
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4ated antithrombotic research. Coronary interventions
rovided the “laboratory” for evaluating heparins, anti-
hrombins, antiplatelet agents, and others. At the same
ime, the healing response led to overdevelopment of tis-
ue leading to restenosis. Discovery of the central role of
ell growth led to research on agents to inhibit this pro-
ess to include antimetabolites, genetic alterations and
ntisense oligonucleotides, radiation therapy, and ulti-
ately cytostatic and cytotoxic agents coupled with a
ontrolled-release mechanism (i.e., drug-eluting stents).
his wave of success produced its own imperative: re-
earch on the solution to impaired endothelial healing.
uch of the funding for research in vascular biology, an-
iogenesis, myogenesis, and related processes has been
timulated by the ripples (problems) emanating from in-
erventional cardiovascular procedures.
mpact on Innovation
pening an artery with a balloon seemed much too sim-
le to many with innovative minds. The era of new de-
ice development for endovascular exploration and therapy
s continuing with a long list of failures and a shorter list
f successes. Consider directional atherectomy, extraction
therectomy, rotary ablation, laser ablation, laser balloons,
pectroscopy, intravascular ultrasound, angioscopy, optical
oherence tomography, distal protection devices, vascular
cclusion devices, and stents. Outside of the coronary
rteries, stent grafts, mitral clips, mitral rings, atrial
ppendage closure devices, atrial and ventricular septal
losure devices, devices for occluding arteriovenous
alformations and aneurysms, and many others have
een developed. Placement of prosthetic aortic valves
ay soon enable safer treatment of the expanding popula-
ion of elderly patients with high-risk aortic stenosis. Less
nvasive innovations seem to be driving the entrepreneur-
al spirit.
Pharmacological innovations have not been far behind,
ith glycoprotein IIb/IIIa agents, thienopyridines, low-
olecular-weight heparins, 10A inhibitors, direct anti-
hrombins, and thrombolytics all being stimulated by the
romise and problems of interventional cardiovascular
edicine. Future implantation of progenitor cells capable
f regenerating myocardium holds out promise for those
ith severe heart failure. pOne should not assume that the pebble thrown was a
ompletely de novo event. Gruentzig’s act would have not
een possible without the innovations of Roentgen, Forss-
ann, Sones, Favalaro, Dotter, and others and would not
ave been successful without extensive experimental prep-
ration. Likewise, the ripples that affect so many aspects of
edicine are not unidirectional, but reflect off distant shores
nd off each other to create new waves for the future.
This journal is in recognition of the accelerating expan-
ion of interventional cardiovascular medicine and is offered
s a vehicle for communicating the continuing ripples—
aves—tsunamis, emanating from “a pebble in a pond.”
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APPENDIX
or an accompanying paper on the “Celebration of Interventional Cardiology,”
Figure 1. Sculpture of Andreas Gruentzig in the room at Heart House
dedicated to “The Father of Interventional Cardiovascular Medicine.”lease see the online version of this paper.
